Carevive at ViVE 2023 Recap Video

John Elliott, VP of Sales at Carevive, shared his insights on the vibrant atmosphere and focused discussions at the ViVE conference. The event brought together a diverse audience of entrepreneurs, capital investors, founders, and health system innovators. John highlighted the increased emphasis on consumerism and patient-centric care, with a particular focus on patient experience and engagement. The conversations around oncology were especially notable, with twice as many discussions compared to the previous year. Carevive’s presence at the NIH booth provided an opportunity to collaborate with various groups, exploring the problems they aim to solve and the desired outcomes. John expressed gratitude for the engaging conversations and looked forward to witnessing the positive impact that arises from collective problem-solving and the ultimate improvement of outcomes.

Energized Conversations and Collaboration:
The ViVE conference provided an energizing environment for discussions and connections. Carevive actively engaged in back-to-back conversations, seizing the opportunity to collaborate with like-minded individuals and groups passionate about enhancing patient care. John’s remarks during a downtime at the conference highlighted the importance of solving problems together and working towards shared goals.

Recent Episodes

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…